Sativa Foundation to fund academic research in to medicinal cannabis

By in
225

Press Release                                                                                                       Monday 25th June 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

Sativa Investments PLC 

 (“Sativa” or “the Company”) 

Sativa Foundation to fund academic research in to medicinal cannabis

Sativa Investments PLC (NEX:SATI), the UK’s only medicinal cannabis investment vehicle, has formed the Sativa Foundation (“The Foundation”) to fund academic research into medicinal cannabis and its benefits to the pharmaceutical and healthcare sectors. The Foundation will award grants to research projects approved by the Foundation’s Advisory Board, which includes Pharmacologist Sir Alasdair Breckenridge, physician and barrister Dr Peter Feldshreiber, physician Dr Stuart Ungar, and founder and Chief Executive Officer of Sativa Investments, Geremy Thomas. Three research grants are already being considered.  

Sativa Investments will have a fiduciary interest in any grant, as each will be conditional on Sativa Research and Development Ltd, a wholly owned subsidiary of Sativa Investments PLC, being entitled to the entire IP and licensing rights to any discovery or other agreed terms. Commercialisation agreements will be agreed between the parties, and Home Office growing licenses will be sought to supply materials to the researchers.

Geremy Thomas said: “Medicinal cannabis in the UK is becoming a major pharmaceutical and healthcare solution to treat patients’ symptoms without the side effects from opioids. Medicinal cannabis needs to be far more thoroughly researched in the UK and Sativa is delighted to be helping to fund it.

“The Board looks forward to help lead medicinal cannabis research in the UK, so its use can be implemented in the best way possible for better patient outcome.”

The Directors of the Company accept responsibility for the contents of this announcement.

– Ends  –

 

For further information please contact:

 

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

 

NEX Exchange Corporate Adviser 
Guy Miller
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630
SativaInvestments@abchurch-group.com

Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.com

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private. 

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience.  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: https://sativainvestments.co.uk/

54321
(0 votes. Average 0 of 5)